MedPage Today: Combination treatment promising for certain leukemia patients
UC expert comments on new study
A combination of low-intensity chemotherapy and an antibody-drug conjugate drug showed promise in a phase 2 trial for older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukemia (ALL).
MedPage Today highlighted the study, and patients in the study had a "significant improvement" in their five-year progression-free survival compared to historical data for this patient set, according to the study's authors.
Emily Curran, MD, medical director of the University of Cincinnati Cancer Center Clinical Trials Office and assistant professor of Internal Medicine in UC's College of Medicine, authored a corresponding commentary on the study, published in The Lancet Hematology.
The study "provides impressive results, with survival outcomes that far exceed historic survival data in older adults with acute lymphocytic leukemia," Curran wrote in the commentary.
Read the MedPage Today article.
Featured photo at top: Dr. Emily Curran examines specimens using a microscope in her lab. Photo/Colleen Kelley/UC Marketing + Brand.
Dermatology Times features UC research of nail squamous cell carcinoma treatment
June 9, 2022
Dermatology Times featured recent research by University of Cincinnati researchers that showed a low recurrence rate of nail squamous cell carcinoma when treated with surgical approaches other than amputation.
Medical News Today: Gene mutation may be a key to lung cancer treatment
September 21, 2022
Medical News Today highlighted recent research led by the University of Cincinnati's Pier Paolo Scaglioni, MD, that found targeting components of lipid metabolism and synthesis could lead to an effective lung cancer treatment.
Cure: FDA approves tablet form of blood cancer treatment
August 5, 2022
The University of Cincinnati's John Byrd, MD, was featured in a Cure article on the FDA's approval of the tablet form of the drug Calquence to treat multiple blood cancers.